At the news
? BEARISHIMPACT 7/10 8-K filed Aug 18, 2026 at 17:00 ET
TScan Therapeutics disclosed that Amgen terminated their Research Collaboration and License Agreement for Crohn's disease, effective November 10, 2026. This ends a partnership that included a $30M upfront payment (received in 2023) and over $500M in potential milestones, with no termination penalty owed by TScan. The loss of future milestone and royalty revenue is a material negative for the company, which has a $50M market cap and no approved products.
- Amgen terminated the Research Collaboration and License Agreement with TScan Therapeutics on August 12, 2026, effective November 10, 2026.
- No early termination penalty is payable by TScan in connection with the termination.
- The agreement provided for a non-refundable upfront payment of $30.0 million (received in 2023), success-based milestone payments of over $500 million in aggregate, and tiered single-digit royalty payments.
- TScan is obligated to wind down its activities under the research plan; licenses granted under the agreement will terminate.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access